When blood-brain barrier crossing adeno-associated viruses (AAVs) are used to deliver the gene for these degraders directly into the brain in a P301S tauopathy mouse model, levels of tau aggregates are reduced without any change in overall tau protein levels33,34. This evidence concerns the gene MAPT and tauopathy.